Pharmacare Premium Claims Pole Position On Pazopanib

Malta-Based Generics Developer Reports Two Successful Bioequivalence Trials

 
• By Dave Wallace

Malta-based generics developer and manufacturer Pharmacare Premium believes it is leading the way on developing a generic pazopanib rival to Novartis’ Votrient cancer treatment for the European market.

Advantage Leader Wooden Figures
Pharmacare Premium says it is leading the pack on pazopanib • Source: Alamy

More from Generics

More from Products